HUP9904026A2 - Sibutraminanalógok alkalmazása diabetes kifejlődésének megelőzésére - Google Patents

Sibutraminanalógok alkalmazása diabetes kifejlődésének megelőzésére

Info

Publication number
HUP9904026A2
HUP9904026A2 HU9904026A HUP9904026A HUP9904026A2 HU P9904026 A2 HUP9904026 A2 HU P9904026A2 HU 9904026 A HU9904026 A HU 9904026A HU P9904026 A HUP9904026 A HU P9904026A HU P9904026 A2 HUP9904026 A2 HU P9904026A2
Authority
HU
Hungary
Prior art keywords
medicinally
methyl
general formula
diabetes
development
Prior art date
Application number
HU9904026A
Other languages
English (en)
Inventor
Clifford James Bailey
Helen Christine Jackson
Robert Brian Jones
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of HUP9904026A2 publication Critical patent/HUP9904026A2/hu
Publication of HUP9904026A3 publication Critical patent/HUP9904026A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)

Abstract

A találmány tárgya sibűtraminanalógők alkalmazása gyógyszerelőállítására az inzűlinrezisztencia csökkentésére őlyan személyeknél,akiknél gyengített glükóztőlerancia vagy nem inzűlinfüggő diabetesmellitűs nem jelentkezett, de akiknél fennáll az ilyen állapőtkifejlődésének főkőzőtt veszélye. A találmány szerint készítmény (I)általánős képletű vegyület -, ahől R1 és R2 egymástól függetlenül hidrőgénatőm vagy metilcsőpőrt - vagyenantiőmere vagy gyógyászatilag elfőgadható sója terápiásan hatásősmennyiségét tartalmazza gyógyászatilag elfőgadható hígítószerrel vagyhőrdőzóval együtt. Az (I) általánős képletű vegyületek közül alegelőnyösebb az N,N-dimetil-1-[1-(4-klór-fenil)-ciklőbűtil]-3-metil-bűtil-amin-hidrőklőrid- mőnőhidrát. ŕ
HU9904026A 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes HUP9904026A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process

Publications (2)

Publication Number Publication Date
HUP9904026A2 true HUP9904026A2 (hu) 2000-05-28
HUP9904026A3 HUP9904026A3 (en) 2000-07-28

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904026A HUP9904026A3 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (hu)
EP (1) EP0927028A1 (hu)
JP (1) JP2001503737A (hu)
KR (1) KR20000048501A (hu)
CN (1) CN1237905A (hu)
AU (1) AU724488B2 (hu)
BG (1) BG64473B1 (hu)
BR (1) BR9711517A (hu)
CA (1) CA2266401C (hu)
CZ (1) CZ93699A3 (hu)
GB (1) GB9619757D0 (hu)
HR (1) HRP970505A2 (hu)
HU (1) HUP9904026A3 (hu)
ID (1) ID18320A (hu)
IL (1) IL128850A (hu)
MY (1) MY116150A (hu)
NO (1) NO991358L (hu)
NZ (1) NZ334580A (hu)
PL (1) PL332305A1 (hu)
RU (1) RU2245709C2 (hu)
SK (1) SK31999A3 (hu)
TR (1) TR199900618T2 (hu)
TW (1) TW580385B (hu)
UA (1) UA64726C2 (hu)
WO (1) WO1998011884A1 (hu)
ZA (1) ZA978450B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
CA2329004C (en) * 1998-06-30 2009-04-14 Takeda Chemical Industries, Ltd. Combination of insulin sensitizer with anorectic for treating or preventing diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
KR100643833B1 (ko) * 1998-11-12 2006-11-10 스미스클라인비이참피이엘시이 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000072810A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
PL375032A1 (en) * 2002-10-05 2005-11-14 Hanmi Pharm.Co, Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
TWI339586B (en) * 2003-10-31 2011-04-01 Takeda Chemical Industries Ltd Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
BRPI0716952A2 (pt) 2006-09-15 2013-10-29 Reviva Pharmaceuticals Inc Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
WO2013102195A1 (en) 2011-12-30 2013-07-04 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
UA64726C2 (uk) 2004-03-15
CA2266401A1 (en) 1998-03-26
TR199900618T2 (xx) 1999-06-21
PL332305A1 (en) 1999-08-30
EP0927028A1 (en) 1999-07-07
HRP970505A2 (en) 1998-08-31
NO991358D0 (no) 1999-03-19
AU724488B2 (en) 2000-09-21
SK31999A3 (en) 1999-12-10
US6617360B1 (en) 2003-09-09
BG64473B1 (bg) 2005-04-30
TW580385B (en) 2004-03-21
NO991358L (no) 1999-03-19
WO1998011884A1 (en) 1998-03-26
ID18320A (id) 1998-03-26
GB9619757D0 (en) 1996-11-06
RU2245709C2 (ru) 2005-02-10
NZ334580A (en) 2000-09-29
JP2001503737A (ja) 2001-03-21
BR9711517A (pt) 1999-08-24
CN1237905A (zh) 1999-12-08
AU4774097A (en) 1998-04-14
MY116150A (en) 2003-11-28
US20040077730A1 (en) 2004-04-22
KR20000048501A (ko) 2000-07-25
HUP9904026A3 (en) 2000-07-28
CZ93699A3 (cs) 1999-08-11
US6174925B1 (en) 2001-01-16
ZA978450B (en) 1999-03-19
IL128850A (en) 2003-07-31
IL128850A0 (en) 2000-01-31
BG103277A (en) 2000-01-31
CA2266401C (en) 2007-01-30

Similar Documents

Publication Publication Date Title
HUP9904026A2 (hu) Sibutraminanalógok alkalmazása diabetes kifejlődésének megelőzésére
ZA95814B (en) Medical treatment
RU99108468A (ru) Применение аналогов сибутрамина для профилактики сахарного диабета
NO865093L (no) Fremgangsmaate for fremstilling av n,n-dimetyl-1-(1-(4-klorfenyl)-cyklobutyl)-3-metylbutylamin.
KR900701261A (ko) 비만증 치료방법
FI944165A0 (fi) Koostumus suun kautta nautittavia valmisteita varten
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
CA2189603A1 (en) Propiophenone derivative and processes for preparing the same
CA2382480A1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP0508488A3 (en) Use of inositol triphosphate for the treatment of diseases associated with metal intoxications
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
RU2003100076A (ru) Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х
HUP0102470A2 (hu) Retinoidrokon receptorok funkcióját szabályozó 1,3-azol-származékok és alkalmazásuk
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
BG103278A (en) Medicamentous treatment
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
DK0935469T3 (da) Anvendelse af væksthormon
CA2180621A1 (fr) Nouveaux derives d'acide aminophenylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR900701763A (ko) 1-아미노-5-할로게노우라실, 그의 제조방법 및 이 화합물을 유효성분으로 함유하는 중추신경억제제
PT785787E (pt) Utilizacao de derivados de 1,5-benzodiazepina para o controlo de esvaziamento gastrico em doentes com diabetes mellitus nao-insulino dependentes
HUP0104388A2 (hu) Béta-agonistákból és további antidiabetikus szerekből álló kombinációk
KR910009257A (ko) 이펜프로딜 및 그의 유도체를 유효성분으로 하는 정신병치료제
Naumenko et al. Correction of arterial blood pressure in adult rats with inherited stress-induced arterial hypertension by enhancement of catecholamine metabolism in early postnatal period
KR880006223A (ko) 12- 할로겐화 포스콜린 유도체, 중간체 및 이의 제조방법, 및 약제로서의 이의 용도
TH52365B (th) การรักษาทางการแพทย์

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees